Get started

Financials · KRMD

KORU Medical Systems Inc. (KRMD) financials

For the twelve months ended Sep 30, 2026, KORU Medical Systems Inc. reported $46.27M of revenue and -$823.4K of net income.

Revenue, TTM
$46.27M
Revenue growth, YoY
+18.4%
Net income, TTM
-$823.4K
Net margin
-1.8%
Free cash flow, TTM
-$387.4K
EPS, diluted, TTM
-$0.02
Cash
$7.36M
Total debt
$332.5K
P/S
3.15
Market cap
$145.9M
Annual revenue$41.13M
FY2016FY2025
Annual net income-$2.64M
FY2016FY2025
Annual free cash flow-$470.1K
FY2016FY2025

KRMD revenue and earnings growth

KRMD revenueQ3 2026$11.57M

Quarter YoY
+11.2%
QoQ
-4.0%
FY YoY
+22.2%
5Y CAGR
+11.2%

KRMD revenue was $11.57M in fiscal Q3 2026 (ended Sep 30, 2026), up 11.2% from a year earlier and down 4.0% from the prior quarter. For the full fiscal 2025 it was $41.13M, up 22.2% from fiscal 2024. Compound annual growth was +11.2% over 5 years. It rose in 6 of the last 7 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

KRMD net incomeQ3 2026$218.1K

QoQ
-13.6%

KRMD net income was $218.1K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$778.0K a year earlier and down 13.6% from the prior quarter. For the full fiscal 2025 it was -$2.64M, compared with -$6.07M in fiscal 2024.

KRMD EPSQ3 2026$0.00

QoQ
-100.0%

KRMD diluted EPS was $0.00 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.02 a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was -$0.06, compared with -$0.13 in fiscal 2024.

KRMD free cash flowQ3 2026-$1.15M

KRMD free cash flow was -$1.15M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $13.0K a year earlier. For the full fiscal 2025 it was -$470.1K, compared with -$1.62M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Feb 28, 2017
FY2016
Feb 29, 2016
Revenue$41.13M$33.65M$28.52M$27.90M$23.49M$24.18M$23.16M$17.35M$12.29M$12.25M
Cost of revenue$15.52M$12.31M$11.81M$12.53M$9.72M$9.24M$8.31M$6.54M$4.72M$4.64M
Gross profit$25.60M$21.33M$16.71M$15.37M$13.77M$14.94M$14.85M$10.81M$7.57M$7.60M
Research and development$4.39M$5.26M$5.74M$4.96M$2.47M$1.30M$740.5K$241.1K$237.5K$207.3K
Selling, general and admin$23.38M$21.63M$20.37M$20.61M$17.86M$12.03M$9.77M$8.20M$7.77M$5.94M
Operating income-$2.97M-$6.45M-$10.27M-$10.78M-$7.03M-$1.25M$585.7K$1.16M-$736.3K$1.18M
Interest expense--------$1.9K$3.4K
Pre-tax income-$2.62M-$6.06M-$9.77M-$10.68M-$6.36M$1.19M$696.4K$1.18M-$776.7K$1.14M
Income tax$21.9K$2.9K$3.97M-$2.01M-$1.80M-$17.8K$132.1K$266.4K-$241.7K$359.7K
Net income-$2.64M-$6.07M-$13.74M-$8.66M-$4.56M-$1.21M$564.3K$910.6K-$535.0K$782.9K
EPS, basic-$0.06-$0.13-$0.30-$0.19-$0.10-$0.03$0.01$0.02-$0.01$0.02
EPS, diluted-$0.06-$0.13-$0.30-$0.19-$0.10-$0.03$0.01$0.02-$0.01$0.02
Diluted shares46.2M45.8M45.6M45.0M44.4M41.9M39.1M38.9M37.9M38.0M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Feb 28, 2017
FY2016
Feb 29, 2016
Cash and equivalents$8.87M$9.58M$11.48M$17.41M$25.33M$27.32M$5.87M$3.74M$3.31M$4.20M
Receivables$5.97M$5.72M$4.05M$3.56M$3.59M$2.57M$3.23M$1.43M$1.50M$1.35M
Inventory$3.68M$2.80M$3.48M$6.40M$6.11M$6.83M$2.39M$2.10M$1.35M$1.04M
Current assets$19.99M$19.13M$20.26M$29.80M$37.32M$37.53M$11.88M$9.03M$6.78M$7.12M
Total assets$28.20M$27.22M$28.46M$42.33M$41.29M$39.92M$13.88M$10.55M$8.17M$8.39M
Current liabilities$8.19M$7.20M$4.45M$6.96M$4.79M$3.67M$2.41M$1.58M$1.39M$1.11M
Total liabilities$11.15M$10.40M$8.11M$11.01M$4.79M$3.76M$2.65M$1.58M$1.49M$1.28M
Shareholders' equity$17.05M$16.81M$20.35M$31.33M$36.50M$36.16M$11.24M$8.96M$6.68M$7.12M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Feb 28, 2017
FY2016
Feb 29, 2016
Operating cash flow$462.4K-$319.7K-$4.89M-$5.40M-$4.32M-$743.3K$320.6K$1.48M-$331.6K$1.91M
Capital expenditures$932.5K$1.30M$782.9K$2.76M$346.2K$920.6K$201.2K$297.0K$203.1K$121.8K
Free cash flow-$470.1K-$1.62M-$5.68M-$8.17M-$4.67M-$1.66M$119.4K$1.18M-$534.7K$1.79M
Investing cash flow-$949.8K-$1.33M-$814.6K-$2.80M-$366.2K-$1.04M$1.31M-$1.73M-$416.3K-$189.5K
Financing cash flow-$221.3K-$248.5K-$218.9K$279.5K$2.71M$23.22M$501.3K$14.4K-$140.7K-$80.6K
Share repurchases------$2.8K---
Stock-based compensation$2.71M$2.62M$2.77M$3.08M$2.71M$1.62M$1.20M$366.1K$205.5K$114.6K
Depreciation and amortization$810.5K$888.5K$870.4K$587.1K$463.1K$418.6K$340.2K$309.3K$300.6K$271.6K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Feb 28, 2017
FY2016
Feb 29, 2016
Revenue growth, YoY22.2%18.0%2.2%18.8%-2.8%4.4%33.5%41.2%0.4%8.9%
Net income growth, YoY-------38.0%--3.9%
EPS growth, YoY-------50.0%--0.0%
Gross margin62.3%63.4%58.6%55.1%58.6%61.8%64.1%62.3%61.6%62.1%
Operating margin-7.2%-19.2%-36.0%-38.6%-29.9%-5.2%2.5%6.7%-6.0%9.6%
Net margin-6.4%-18.0%-48.2%-31.0%-19.4%-5.0%2.4%5.2%-4.4%6.4%
Free cash flow margin-1.1%-4.8%-19.9%-29.3%-19.9%-6.9%0.5%6.8%-4.3%14.6%
Return on equity-15.5%-36.1%-67.5%-27.6%-12.5%-3.4%5.0%10.2%-8.0%11.0%
Return on assets-9.4%-22.3%-48.3%-20.5%-11.0%-3.0%4.1%8.6%-6.5%9.3%
Current ratio2.442.664.554.287.7910.244.945.704.886.43

Source: XBRL data KORU Medical Systems Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KRMD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KRMD$46.27M+18.4%-$823.4K-1.8%$145.9M
SYK$26.30B+7.9%$3.62B13.8%$123.45B
MMM$25.25B+1.7%$3.54B14.0%$97.85B
BSX$21.07B+8.9%$3.50B16.6%$64.78B
BDX$23.25B+17.4%$941.00M4.0%$57.91B
MDLN$30.68B-$683.00M2.2%$53.81B
RMD$5.73B+9.0%$1.59B27.8%$32.93B
DXCM$5.10B+13.0%$991.00M19.4%$29.81B
WST$3.40B+12.6%$638.90M18.8%$28.74B

KRMD FAQ

9 questions
  • What is KRMD revenue?
    KORU Medical Systems Inc. (KRMD) reported $46.27M of revenue for the twelve months ended Sep 30, 2026. That is up 18.4% from the year before. Revenue for fiscal 2025 was $41.13M.
  • Is KRMD profitable?
    No. KORU Medical Systems Inc. reported a net loss of $823.4K for the twelve months ended Sep 30, 2026.
  • How much cash and debt does KRMD have?
    KORU Medical Systems Inc. reported $7.36M in cash and cash equivalents and $332.5K of debt on its most recent balance sheet in SEC filings.
  • How fast is KRMD revenue growing?
    KORU Medical Systems Inc.'s revenue changed +22.2% in fiscal 2025, to $41.13M. Its compound annual growth rate was +11.2% over 5 years.
  • What is KRMD gross margin?
    KORU Medical Systems Inc.'s gross profit was $29.44M on $46.27M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 63.6%.
  • What is KRMD free cash flow?
    KORU Medical Systems Inc. generated -$387.4K of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $442.7K less capital expenditures.
  • What is KRMD earnings per share?
    Diluted earnings per share were -$0.02 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KRMD last report financial results?
    The latest statements here come from KORU Medical Systems Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this KRMD financial data come from?
    Quantisnow builds these statements from the structured XBRL data KORU Medical Systems Inc. files with the SEC. It is provided for information only and is not investment advice.